PURPOSE: The type 2 cannabinoid receptor (CB2R) is part of the human endocannabinoid system and is involved in central and peripheral inflammatory processes. In vivo imaging of the CB2R would allow study of several (neuro)inflammatory disorders. In this study we have investigated the safety and tolerability of [11C]-NE40, a CB2R positron emission tomography (PET) ligand, in healthy human male subjects and determined its biodistribution and radiation dosimetry. PROCEDURE: Six healthy male subjects (age 20-65 years) underwent a dynamic series of nine whole-body PET/CT scans for up to 140 min, after injection of an average bolus of 286 MBq of [11C]-NE40. Organ absorbed and total effective doses were calculated through OLINDA. RESULTS: [11C]-NE40 showed high initial uptake in the spleen and a predominant hepatobiliary excretion. In the brain, rapid uptake and swift washout were seen. Organ absorbed doses were largest for the small intestine and liver, with 15.6 and 11.5 μGy/MBq, respectively. The mean effective dose was 3.64±0.81 μSv/MBq. There were no changes with aging observed. No adverse events were encountered. CONCLUSIONS: This first-in-man study of [11C]-NE40 showed an expected biodistribution compatible with lymphoid tissue uptake and appropriate fast brain kinetics in the healthy human brain, underscoring the potential of this tracer for further application in central and peripheral inflammation imaging. The effective dose is within the typical expected range for 11C ligands.
PURPOSE: The type 2 cannabinoid receptor (CB2R) is part of the human endocannabinoid system and is involved in central and peripheral inflammatory processes. In vivo imaging of the CB2R would allow study of several (neuro)inflammatory disorders. In this study we have investigated the safety and tolerability of [11C]-NE40, a CB2R positron emission tomography (PET) ligand, in healthy human male subjects and determined its biodistribution and radiation dosimetry. PROCEDURE: Six healthy male subjects (age 20-65 years) underwent a dynamic series of nine whole-body PET/CT scans for up to 140 min, after injection of an average bolus of 286 MBq of [11C]-NE40. Organ absorbed and total effective doses were calculated through OLINDA. RESULTS:[11C]-NE40 showed high initial uptake in the spleen and a predominant hepatobiliary excretion. In the brain, rapid uptake and swift washout were seen. Organ absorbed doses were largest for the small intestine and liver, with 15.6 and 11.5 μGy/MBq, respectively. The mean effective dose was 3.64±0.81 μSv/MBq. There were no changes with aging observed. No adverse events were encountered. CONCLUSIONS: This first-in-man study of [11C]-NE40 showed an expected biodistribution compatible with lymphoid tissue uptake and appropriate fast brain kinetics in the healthy human brain, underscoring the potential of this tracer for further application in central and peripheral inflammation imaging. The effective dose is within the typical expected range for 11C ligands.
Authors: David A Price; Alex A Martinez; Alexandre Seillier; Wouter Koek; Yolanda Acosta; Elizabeth Fernandez; Randy Strong; Beat Lutz; Giovanni Marsicano; James L Roberts; Andrea Giuffrida Journal: Eur J Neurosci Date: 2009-05-21 Impact factor: 3.386
Authors: Q-R Liu; C-H Pan; A Hishimoto; C-Y Li; Z-X Xi; A Llorente-Berzal; M-P Viveros; H Ishiguro; T Arinami; E S Onaivi; G R Uhl Journal: Genes Brain Behav Date: 2009-06-03 Impact factor: 3.449
Authors: Katri H Raitio; Juha R Savinainen; Tapio Nevalainen; Tomi Järvinen; Jouko Vepsäläinen Journal: Chem Biol Drug Des Date: 2006-12 Impact factor: 2.817
Authors: Nele Evens; Caroline Vandeputte; Charlotte Coolen; Peter Janssen; Raf Sciot; Veerle Baekelandt; Alfons M Verbruggen; Zeger Debyser; Koen Van Laere; Guy M Bormans Journal: Nucl Med Biol Date: 2011-12-11 Impact factor: 2.408
Authors: Koen Van Laere; Michel Koole; Sandra M Sanabria Bohorquez; Karolien Goffin; Ilonka Guenther; Marie J Belanger; Josee Cote; Paul Rothenberg; Inge De Lepeleire; Igor D Grachev; Richard J Hargreaves; Guy Bormans; H Donald Burns Journal: J Nucl Med Date: 2008-02-20 Impact factor: 10.057
Authors: Nele Evens; Barbara Bosier; Brian J Lavey; Joseph A Kozlowski; Peter Vermaelen; Luc Baudemprez; Roger Busson; Didier M Lambert; Koen Van Laere; Alfons M Verbruggen; Guy M Bormans Journal: Nucl Med Biol Date: 2008-10 Impact factor: 2.408
Authors: C C Felder; K E Joyce; E M Briley; J Mansouri; K Mackie; O Blond; Y Lai; A L Ma; R L Mitchell Journal: Mol Pharmacol Date: 1995-09 Impact factor: 4.436
Authors: Chris L Schaich; Hossam A Shaltout; Megan Grabenauer; Brian F Thomas; Patricia E Gallagher; Allyn C Howlett; Debra I Diz Journal: J Cardiovasc Pharmacol Date: 2015-05 Impact factor: 3.105
Authors: Michel Koole; Talakad G Lohith; John L Valentine; Idriss Bennacef; Ruben Declercq; Tom Reynders; Kerry Riffel; Sofie Celen; Kim Serdons; Guy Bormans; Sandrine Ferry-Martin; Philippe Laroque; Abbas Walji; Eric D Hostetler; Richard J Briscoe; Jan de Hoon; Cyrille Sur; Koen Van Laere; Arie Struyk Journal: Mol Imaging Biol Date: 2020-02 Impact factor: 3.488
Authors: Stefanie M A Willekens; Donatienne Van Weehaeghe; Philip Van Damme; Koen Van Laere Journal: Eur J Nucl Med Mol Imaging Date: 2016-12-08 Impact factor: 9.236
Authors: Alena V Savonenko; Tatiana Melnikova; Yuchuan Wang; Hayden Ravert; Yongjun Gao; Jeremy Koppel; Deidre Lee; Olga Pletnikova; Eugenia Cho; Nuzhat Sayyida; Andrew Hiatt; Juan Troncoso; Peter Davies; Robert F Dannals; Martin G Pomper; Andrew G Horti Journal: PLoS One Date: 2015-06-18 Impact factor: 3.240